Background Lysosomal storage diseases (LSDs) are inborn errors of metabolism resulting from 50 different inherited disorders. The increasing availability of treatments and the importance of early intervention have stimulated newborn screening (NBS) to diagnose LSDs and permit early intervention to prevent irreversible impairment or severe disability. We present our experience screening newborns in North East Italy to identify neonates with Mucopolysaccharidosis type I (MPS I) and Pompe, Fabry, and Gaucher diseases. Methods Activities of acid β-glucocerebrosidase (ABG; Gaucher), acid α-glucosidase (GAA; Pompe), acid αgalactosidase (GLA; Fabry), and acid α-L-iduronidase (IDUA; MPS-I) in dried blood spots (DBS) from all newborns during a 17-month period were determined by multiplexed tandem mass spectrometry (MS/MS) using the NeoLSD ® as-Robert J. Desnick and Alessandro P. Burlina contributed equally to this work.
Introduction
Lysosomal storage diseases (LSDs) are inborn errors of metabolism that include~50 different inherited disorders. Together, they have a reported combined incidence of at least one in 1500 to one in 7000 newborns (Meikle et al 1999; Fletcher 2006; Fuller et al 2006) . LSDs are caused by the deficient or absent activity of a specific lysosomal enzyme or transporter, resulting in the accumulation of uncatabolized macromolecular substrates within lysosomes (Wraith 2002; Schultz et al 2011; Klein and Futerman 2013) .
The current evaluation and increasing availability of treatment options for LSDs, including enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (alone or in combination with ERT), small molecular weight pharmacologic chaperones, and gene therapy have stimulated efforts to screen newborns (Marsden and Levy 2010; Gelb et al 2015; Li et al 2004) since early intervention in certain LSDs is essential to prevent or minimize the irreversible organ damage associated with these progressive disorders and to improve longterm clinical outcomes (Chien et al 2009) .
The recent introduction of tandem mass spectrometry (MS/ MS) methods to analyze proteins and substrates in dried blood spots (DBS) has facilitated and expanded the diseases detected in newborn screening programs (NBS) (Hoffmann et al 2014) . Currently, many programs in developed countries have used the MS/MS technology to detect newborns with 40 to 50 severe diseases (Wilken et al 2003; Villoria et al 2016; Landau et al 2017) . Nevertheless, the choice of disease panels for expanded NBS (ENBS) is still controversial as reflected in the different disease panels in screening programs around the world. In Europe, the NBS programs include a relatively limited number of disorders (Hoffmann et al 2014) (Kemper et al 2014; Singh 2016) . Pilot LSD screening programs have been implemented in a number of countries worldwide (Orsini et al 2009; Marsden and Levy 2010; Liao et al 2014; Gelb et al 2015; Matern et al 2015; Elliott et al 2016) , including Italy (Spada et al 2006; Paciotti et al 2012) . Such programs have shown that NBS for LSDs is feasible and economically justifiable for extension to large populations (Mechtler et al 2012; Hopkins et al 2015; Navarrete-Martinez et al 2017) .
In 2014, the Regional Health Government of North East Italy expanded its NBS program to include MS/MS. The current panel includes 24 metabolic defects (amino acid, urea cycle, organic acid, and fatty acid β-oxidation defects). Recently, the panel was increased to screen for LSDs.
Here, we report our experience, screening 44,411 successive newborns in North East Italy during a 17-month period (September 2015 to January 2017). In our study, we evaluated a multiplexed assay for Fabry disease, Pompe disease, Gaucher disease, and MPS I, and assessed its effectiveness for detecting these LSDs in neonates. We also determined the causative mutations and estimated the incidence of affected newborns for these four LSDs.
Materials and methods

Study population
DBS from 44,411 newborns were collected consecutively by the Regional North East Italy ENBS program after informed consent was obtained from a parent. The DBS were assayed for the enzymes deficient in each disease: Fabry disease (αgalactosidase A [GLA]), Pompe disease (acid α-glucosidase [GAA]), Gaucher disease (acid β-glucocerebrosidase [ABG]), and mucopolysaccharidosis type I (MPS I; acid α-L-iduronidase [IDUA] ). According to the NBS protocol, samples were collected between 36 and 48 h of life, on the same card that the other NBS tests were collected; a second sample was required for premature babies (<34 gestational weeks and/or weight < 2000 g) and for sick newborns (those receiving transfusions or parenteral nutrition). DBS were analyzed the day they were received, and then the DBS cards were placed into plastic bags and stored at −20°C for at least 5 years after analysis.
Determination of enzyme activities of four LSDs by LC-MS/MS
The NeoLSD ® kit from PerkinElmer (Turku, Finland) contained the buffer, mobile phase, substrates, and internal standards for assaying the DBS activities: GAA, GLA, IDUA, ABG, ASM (acid sphingomyelinase), and GALC (βgalactosidase); the mobile phase was also included. Ethyl acetate HPLC grade (EA) was purchased from Carlo Erba (Milan, Italy). Methanol (MeOH) and acetonitrile LC-MS grade were from Sigma-Aldrich (Milan, Italy). Quality controls were provided by PerkinElmer and the Centers for Disease Control and Prevention, USA. Flow injection-MS/ MS analysis was performed on the same MS/MS instruments routinely used for the expanded neonatal screening.
The preparation and analysis of the six lysosomal enzyme activities by LC-MS/MS has been previously reported (Scott et al 2013; Elliott et al 2016; Mashima et al 2016; Kubaski et al 2017) . Briefly, on day 1, 30 μL of the incubation cocktail containing buffers, substrates, and internal standards for the six enzymes were added to a 3.2 mm DBS and incubated for 18 h at 37°C with orbital shaking at 400 rpm. On day 2 the reaction was stopped with 100 μL of MeOH:EA and the mixed solution transferred to a deep well plate. Liquid-liquid extraction was performed by adding 400 μL of EA and 200 μL of water; the solution was mixed with a pipette (10 times). After centrifugation (700 g × 5 min), 50 μL of the top layer was transferred to a new low volume plate, dried under nitrogen, and re-suspended with 100 μL of mobile phase. The workflow of the sample preparation and multiple reaction monitoring (MRM) settings of the Waters Acquity TQD ultra performance liquid mass chromatographic system mass spectrometer instrument and chromatograms are shown in Suppl. Fig. S1 . We did not collect assay data for Krabbe disease (GALC) and Niemann-Pick type A/B (ASM) diseases even though the substrates are included in the multiplex assay mixture. Lysosomal enzymatic activities were expressed as μmol/L/h (μM/h). The mean of the blank values was subtracted from each enzyme activity to give the individual activity values (Fig. 1 ).
Assay cutoff values
Residual and de-identified DBS samples from more than 3500 NBS specimens were used for the pre-pilot enzymatic activity cutoff determinations. The specimens were obtained from our screening service and stored at 18°C in an air conditioned room and used within 6 months.
Forty-one patients with confirmed LSDs, including 14 Gaucher, six neonatal-onset Pompe, 19 Fabry disease, and two MPS I patients were analyzed. The spots were collected after diagnosis and all samples had low enzyme activities that could be clearly distinguished from those of healthy newborns, with the exception of female patients tested for Fabry disease, for whom the enzyme activity assay does not reliably discern heterozygosity.
Provisional cutoffs were set for the pre-pilot study and the first 9 months of screening. According to the enzyme activity we defined two cutoff levels: a slightly elevated value between 0.2 multiple of the median (MOM) and the 0.25 percentile (borderline values) and lower values below 0.2 MOM (high risk value; Table 1 ). Both these cutoff values were validated with known clinical case controls; the high-risk cutoff value was chosen because it enabled detection of positive cases while avoiding too many recalls from the newborn screening process (Fig. 2 ). The following cutoff system was used: if the enzymatic value was below the high-risk cutoff, a second spot was requested. If the activity of the second spot was still below the cutoff, the infant was referred to our unit for confirmatory testing and clinical follow-up ( Fig. 3 ).
Clinical and biochemical assessments
Different assessments were performed depending on the disease, including clinical evaluation, mutational analysis (patients and parents), substrate quantification, and/or enzyme activities in leucocytes/lymphocytes. For Pompe disease, the assessments included electrocardiogram (ECG), echocardiography, and blood tests, including creatine phosphokinase (CPK), aspartate aminotransferase (AST), and alanine aminotransferase (ALT). For Gaucher disease, plasma glucosylsphingosine (GlcSPh) was assayed. For Fabry disease, plasma globotriaosylsphingosine (LysoGb3); and for MPS I urinary GAG analyses were performed.
Results
Study population
Of the 44,411 newborns screened for the four LSDs using the NeoLSD ® assay system, 40 (0.09%) had an enzyme activity below 0.2 MOM and were recalled for collection of a second DBS (Table 2) . Low activity was confirmed in 20 (50%) neonates, who subsequently had confirmatory testing.
Confirmatory clinical studies and diagnostic biochemical and mutation analyses confirmed that ten newborns were affected by a LSD (two with Pompe disease, two with Gaucher disease, five males with Fabry disease, one with MPS I disease). All other newborns had a mutation of unknown clinical significance or known pseudodeficiency allele (Table 3) .
The ten confirmed newborns had a total incidence of one in 4441 births and the positive predictive value (PPV) for each disorder screened is shown in Table 2 . The PPV was calculated as the number of confirmed positive patients divided by the number of positives in the first screening sample for each disorder. Table 3 presents the biochemical and mutational analyses for newborns who tested positive in screening.
For ABG (Gaucher disease), both newborns were homozygous for the mutation encoding p.Asn370Ser, the most common type I Gaucher genotype which is frequent in the Ashkenazi Jewish population (Mistry 2012) . The clinical manifestations among p.Asn370Ser ABG, acid β-glucocerebrosidase; GAA, acid α-glucosidase; GLA, acid α-galactosidase; IDUA, acid α-Liduronidase; MOM, multiple of the median homozygotes are variable, ranging from childhood onset of hepatosplenomegaly to onset in later adulthood. The plasma GlcSPh of patient 1 was evaluated (9.58 nmol/L; normal value 1.15-3.25), and was consistent with that in type 1 Gaucher patients (Murugesan et al 2016) .
For GAA (Pompe disease) screening, patients 1 and 2 had the lowest activity (Table 3) ; they were compound heterozygotes for the same mutations in trans, c.32-13 T > G and c.236_246del. Both newborns were from North Africa and presented with positive biochemical tests for serum CPK, ALT, and AST. ECG and echocardiography showed slightly enlarged hearts, indicating a juvenile form of Pompe disease. Treatment with ERT was promptly initiated. Patients 4, 5, and 6 who had low GAA activity had normal serum CPK, ALT, and AST levels, and their genotypes indicated known pseudodeficiency alleles or a variant of unknown significance (Table 3) .
For X-linked GLA (Fabry disease) testing, all five neonates were males who presented with known pathogenic mutations (Table 3) . Patient 1 had the later-onset mutation encoding p.Asn215Ser, a disease-causing mutation often limited to the heart (Germain et al 2017) . Patient 2 had a later-onset mutation encoding p.Arg363His, which was previously reported, and recent structural studies suggested its possible role in the enzyme destabilization (Serebrinsky et al 2015) . Patient 3 had a mutation encoding p.Arg356Gly, which was reported in a recent study of two affected males who had different clinical manifestations; one presented with the classic phenotype and the other a later-onset phenotype with primary renal involvement (Pan et al 2016) . Patients 4 and 5 had the later-onset mutation, IVS4 + 919G > A, which is common in the Taiwanese population, having primarily heart involvement (Hsu et al 2016) . Increased levels of plasma LysoGb3 were observed in patients 1, 2, and 3 (1.01, 1.02, and 2.17 nMol/L respectively; normal <0.46), with levels similar to those previously reported for later-onset Fabry disease (Serebrinsky et al 2015) . LysoGb3 was slightly elevated in one of the two newborns with the IVS4 + 919G > A mutation (0.52 nMol/L). For IDUA (MPS I) testing, one newborn was homozygous for an IDUA mutation encoding p.Pro553Arg, which was predictive of the MPS I Hurler/Scheie phenotype (Al-Sannaa et al 2015; Tebani et al 2016) . In our set of screened patients, there was a high incidence of variants known to be pseudodeficiency alleles (e.g., encoding p.Ala79Thr, p.His82Gln, p.Asp223Asn) of which p.Ala79Thr is the most common pseudodeficiency allele in newborns of African descent and has been reported in the African-American population (Clarke et al 2017) . Two newborns (patients 2 and 5) were identified as carriers of a severe pathogenic mutation and a pseudodeficiency allele (Table 3) .
Of the ten LSD newborns diagnosed in this study, patients suffering from Pompe disease and MPS I were treated by ERT. Pompe patients were cross-reactive immunological material (CRIM) positive, and they responded very well to the treatment.
Discussion
Screening newborns for LSDs has gained increasing importance as the number of therapeutic options has expanded and the evidence base for early intervention and improved outcomes has been clearly demonstrated for MPS I and Pompe disease (Chien et al 2009; Clarke et al 2017) . Before implementing population-based NBS programs for inherited disorders, a number of issues require consideration, including the availability and efficacy of treatment options, age at onset of clinical manifestations, well known natural history and prognosis, the ability of parents to engage in reproductive decision-making, and provision of appropriate resources for follow-up (Lisi and McCandless 2016) . Although clinically asymptomatic at birth, certain LSDs are rapidly progressive and develop profound irreversible long-term impairment or disabilities. Thus, LSDs are good candidates for NBS and early therapeutic intervention.
The early diagnosis of LSDs at the asymptomatic/ presymptomatic stage is recognized as a valid public health objective, and the inclusion of LSDs in screening protocols for newborns is becoming more widespread internationally. Screening methods that provide a robust differentiation between affected and non-affected individuals can help to minimize false positives and avoid unnecessary treatment. Of the LSDs, Pompe disease, MPS I, and MPS II are considered the most favored for inclusion in screening programs, with Fabry and Gaucher disease somewhat less favored and Krabbe disease being the least favored for NBS (Lisi and McCandless 2016) .
NBS for LSDs has been controversial, primarily because of two major issues. First is the fact that patients with both the early-onset and later-onset subtypes of LSDs are diagnosed by NBS. That newborns with the later-onset phenotypes are frequently diagnosed presents issues for their physicians and especially for their parents. Whereas early treatment has been shown to be effective for certain rapidly progressive infantileonset LSDs, (e.g., infantile Pompe disease), the onset of signs and symptoms for the later-onset subtypes is variable (e.g., Fabry, Pompe, and MPS-IS) and the initiation of treatment depends on the occurrence of the first signs or symptoms. The second major issue relates to the impact of the diagnosis, both medically and psychologically, on the parents of newborns with later-onset subtypes. The parents and family members must be reassured that the newborn will most likely have a normal childhood and adolescence (especially for Fabry, Gaucher Type 1, etc.). LSD expert physicians should evaluate children diagnosed as newborns with the later-onset subtypes annually, and reassure the parents that the signs and/or symptoms have not occurred, and that annual evaluations will determine when therapy is needed. Our preliminary experience from the NBS program in North East Italy suggests that screening for LSDs is feasible and appears to be effective, and can be extended to the larger Italian newborn population. The multiplexed NeoLSD ® assay system (PerkinElmer) for Pompe, Fabry, Gaucher, and MPS I was successfully integrated into the routine workflow of the Padova Newborn Screening Laboratory and performed well on DBS screening. This reflects the experience of other investigators who have used similar MS/MS methodology to identify newborns at risk for LSDs . Of note, it has been recently demonstrated that the analytical range of the mass spectrometry methods for screening is wider than that of the fluorometric methods, providing a more accurate value of enzymatic activity, especially for very low values. This allows for better differentiation between patients with pathogenic mutations, pseudodeficiency alleles, and/or benign variants at the time of screening which may reduce the number of false positives (Kumar et al 2015; Liao et al 2017) .
The diagnosis of a pathogenic genotype was confirmed in ten of the 44,411 tested newborns, which corresponds to a combined incidence of one in 4441 births. The combined frequencies of the four LSDs identified in our study are similar to those detected in other screening studies, including the two previous Italian studies (Spada et al 2006; Paciotti et al 2012) . Paciotti and colleagues conducted a pilot NBS program in the Umbria region of Italy (using a fluorimetric assay) for the same four LSDs. A total of 3403 newborns were screened for GAA, ABG, GLA, and IDUA activities in DBS (Paciotti et al 2012) . They found enzyme levels below 25% of the mean normal activities in a total of 37 neonates; 12 (0.35%), eight (0.23%), four (0.12%), and 13 (0.38%) for GAA, ABG, GLA, and IDUA, respectively. A second blood spot obtained from all 37 neonates was tested, resulting in three of 12 neonates having low GAA, four of eight having low ABG and three of 13 having low IDUA activities, while the remaining 27, including all four with initial low GLA activities, had higher repeat activities which were above the cutoff values. Subsequent testing of all ten positive neonates confirmed a decreased level of ABG activity for only one neonate, and a potential, currently asymptomatic, Gaucher patient was identified based on residual enzymatic activity determined in leucocytes and on molecular analysis.
Interestingly, in the first phase of our screening program before the adjustment of the cutoff level for GLA activity, three neonates with the mutation encoding p.Ala143Thr were detected. These mutations were all associated with high levels of residual enzyme activity (~29% of mean normal activity) and normal levels of plasma lysoGb3 (see Suppl. Table 1 ). Recently, Lenders et al reported their retrospective analysis on 25 adult patients (ten males) with the mutation p.A143T. Most male patients had a high residual enzyme activity with normal plasma lysoGb3 levels. They concluded that the mutation p.A143T could be considered a "neutral variant or a possible modifier instead of a disease-causing mutation" (Lenders et al 2016) . One boy had the mutation p.T246I, not previously reported, which indicated that isoleucine was substituted for threonine at the 246th amino acid of GLA. He had a high level of residual enzymatic activity (34%) and a normal level of lysoGb3 (0.27 nMol/L).
We identified two boys with the Chinese mutation IVS4 + 919G > A. The levels of lysoGb3 was normal in one patient and slightly elevated in the other (0.54 nMol/L). Patients with this intronic mutation have been extensively studied by Taiwanese researchers. Even though most of the studies describe adult patients with Fabry disease, Liao et al reported levels of Gb3 and lysoGb3 in subjects ranging in age from newborn to 8 years old. Approximately 70% of male newborns had elevated plasma levels of lysoGb3 and the authors stated that high levels correlated with increasing age (Liao et al 2013) .
The neonates who tested positive in our study after the second screening were confirmed through assessment of clinical signs and symptoms, biochemical analyses, and mutation analyses. Mutation analyses are not always able to identify the phenotypic subtype of the disease (e.g., early-vs. later-onset) and to determine if a newly recognized missense or splicing mutation is pathologic or benign. Therefore, our diagnostic algorithm included biomarker studies in blood, as well as clinical assessments. We measured plasma biomarkers by LC-MS/MS, lysoGb3, and GlcSph, for Fabry and Gaucher disease, respectively. In one newborn with type 1 Gaucher disease, the plasma GlcSph level was already elevated at the time of confirmatory testing even though he had no clinical manifestations. Similar findings were present in three of the males with Fabry disease who had elevated lysoGb3 levels. For MPS I, we measured heparan sulfate and dermatan sulfate in urine by MS/MS. One patient (of Moroccan origin) had a very high level of GAG and a mutation reported in a Hurler/Scheie patient (Al-Sannaa et al 2015; Tebani et al 2016) . For this patient, ERT was started at the age of 1 month. Of note, our screening revealed a high incidence of these disorders. However, most had later-onset phenotypes. In all the other patients with low enzyme activities, no abnormal metabolites were identified, and the results of molecular analyses confirmed that they had pseudodeficiency alleles.
Our data are similar to the retrospective study published by Dionisi-Vici and colleagues. Before screening for LSDs was introduced in Italy, there were exhaustive efforts to determine overall and disease-specific incidence values for various inborn errors of metabolism in the Italian pediatric population (Dionisi-Vici et al 2002) . Relevant to the present study, they reported that newborn screening for all types of inborn errors, including the LSDs, was feasible, and their findings provided guidance for Italian public health policy decisions. With some exceptions, the genetic background of Italians has been relatively homogenous and indicative of a population with a low consanguinity rate (Dionisi-Vici et al 2002) . Dionisi-Vici and colleagues found that no particular geographic area or ethnic group was at a higher risk for LSDs. In contrast, our data showed that recent immigration from Africa reflected a different population profile in comparison to that reported by Dionisi-Vici (Dionisi-Vici et al 2002) . Many of our patients were of African origin from families that were consanguineous.
In another NBS study, conducted in the Piemonte Region of Italy, Spada and colleagues found a high incidence of lateronset Fabry disease in male neonates (Spada et al 2006) . They screened 37,104 consecutive male newborns for GLA (measured by a fluorometric assay); infants who were enzymedeficient were retested and those found to be Bdoubly screened-positive^had their diagnosis confirmed by enzyme and mutation analyses, as was the case in our study. The overall high incidence of one in 3100 affected males resulted from their finding of only one newborn with the Classic phenotype (one in 37,000), while 11 were classified as having the lateronset phenotype (one in 3360). On retrospective analysis, it is now clear that four of the newborns classified as having the later-onset phenotype actually had previously unrecognized benign mutations, three encoding p.Ala143Thr and one neonate encoding p.Arg118Cys (Ferreira et al 2015) . Thus, the overall revised incidence for the Spada study would be one in 4625. As outlined above, our data suggest an overall incidence of one in 8882 for Fabry disease, which is lower than the revised value from the Spada study (Spada et al 2006) .
This study has some limitations. Some lysosomal diseases screened do not occur in the neonatal period, particularly the later-onset phenotypes of all four LSDs tested. For example, Gaucher disease has three major phenotypes, and the infantile and juvenile are severe neuropathic phenotypes (types 2 and 3) that would be detected. However, ERT has not proven effective for their neurodegenerative manifestations. For the type 1 nonneuronopathic phenotype, patients can present in childhood and early recognition will allow the patient to be followed and treated when the first clinical signs appear. For Fabry disease, our screening program identified neonates whose older family members were subsequently diagnosed and entered in a program of clinical and biochemical follow-up.
Another limitation is that the number of newborns tested was too small to reliably determine the incidence of these diseases, although the numbers are similar to those reported by Dionisi-Vici et al (Dionisi-Vici et al 2002) . There is also the risk of needless anxiety and unnecessary medical intervention in patients that are asymptomatic at diagnosis, and have a diagnosis of a later-onset phenotype that may remain asymptomatic until adulthood. Therefore, follow-up should not be restricted to only medical concerns, but also should include appropriate supportive and psychosocial care (Peake et al 2016) .
Finally, the higher incidence of later-onset Fabry patients or neonates with later-onset phenotypes for other LSDs raises additional ethical issues, as there is a risk of medicalization of the child and adding to parental stress by identifying a form of a disease in which symptoms do not manifest until late adolescence or adulthood (Lisi and McCandless 2016) . Notwithstanding this reservation, NBS for LSDs can be considered beneficial for those LSDs for which there are established treatment options that delay or halt the progression of the disease and/or improve long-term outcomes, particularly where it has been determined that outcomes are more favorable when treatment is initiated before the disease becomes irreversibly severe.
In conclusion, the NeoLSD ® MS/MS assay system for DBS screening proved effective in identifying neonates at risk for LSDs in this population-based NBS program. Establishing cutoff values before starting a screening program is essential to avoid a high number of false positives, which are a source of needless anxiety and unnecessary medical interventions. Long-term follow-up of the affected infants may provide important information about the natural history of the disease and their specific mutations, and should allow for optimized treatment outcomes.
